Archives

  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-11
  • 2018-10
  • 2018-07

    • SM-102 Lipid Nanoparticles: Optimizing mRNA Delivery & Va...

    2026-01-22

    SM-102 Lipid Nanoparticles: Optimizing mRNA Delivery & Vaccine Development

    Executive Summary: SM-102 is an amino cationic lipid optimized for the formation of lipid nanoparticles (LNPs) that enable efficient mRNA delivery (APExBIO, product page). It demonstrates effective regulation of erg-mediated K+ current (ierg) in GH cells at 100–300 μM concentrations, supporting its role in signaling modulation (APExBIO, C1042 datasheet). SM-102-based LNPs are validated by both empirical and machine-learning-guided studies as robust vectors for mRNA vaccine and therapeutic delivery (Wang et al., 2022). Its integration in clinical mRNA vaccine workflows underscores its translational utility. Current research benchmarks its performance, limitations, and workflow parameters for reproducible use in advanced drug delivery systems.

    Biological Rationale

    Efficient intracellular delivery of mRNA is a cornerstone of next-generation vaccine and gene therapy platforms. Naked mRNA is rapidly degraded by extracellular nucleases and fails to traverse the cellular membrane due to its size and negative charge (Wang et al., 2022). Lipid nanoparticles (LNPs) solve this by encapsulating and protecting mRNA, facilitating cellular uptake via endocytosis. Among LNP components, ionizable cationic lipids—like SM-102—are critical for compacting mRNA and enabling endosomal escape. SM-102, as supplied by APExBIO, is designed to form stable LNPs with optimized charge properties at physiological and endosomal pH, enhancing both delivery efficiency and safety (product page). For a broader mechanistic context, see SM-102 and the Next Era of mRNA Delivery, which explores strategic innovation; this article focuses on atomic, workflow-relevant facts.

    Mechanism of Action of SM-102

    SM-102 is an amino cationic lipid with a pKa that enables it to remain nearly neutral at physiological pH and become positively charged in acidic endosomal environments. Upon LNP formation, SM-102 binds and condenses mRNA through electrostatic interactions. Following cellular uptake, acidification in the endosome protonates SM-102, disrupting the endosomal membrane and promoting mRNA release into the cytosol. Notably, SM-102 at 100–300 μM concentrations modulates the ierg potassium current in GH cells, demonstrating biological activity relevant to cellular signaling pathways (APExBIO, C1042 datasheet). For a deep dive into mechanism and empirical data, see SM-102 in Lipid Nanoparticles: Mechanisms, Evidence & Limits; this article updates with the latest machine learning and experimental benchmarks.

    Evidence & Benchmarks

    • SM-102 is a core ionizable lipid in LNPs used for mRNA vaccine delivery, validated in both experimental and computational workflows (Wang et al., 2022).
    • mRNA vaccine LNP formulations with SM-102 demonstrate high encapsulation efficiency (>90%) and promote robust protein expression in vitro (Wang et al., Tables 1–2, DOI).
    • Machine learning models (LightGBM) predict SM-102 LNPs yield functional IgG titers in vivo, with R2 > 0.87 versus observed outcomes (Wang et al., Fig. 3, DOI).
    • In animal models, LNPs using DLin-MC3-DMA (MC3) as the ionizable lipid outperformed SM-102 in IgG titer, but SM-102 remained a validated, widely-used alternative (Wang et al., 2022).
    • SM-102 LNPs enable efficient mRNA delivery with low cytotoxicity at tested concentrations (100–300 μM), as shown in GH cell models (APExBIO, C1042 datasheet).

    Applications, Limits & Misconceptions

    SM-102’s primary application is in the formulation of LNPs for mRNA delivery, underpinning both vaccine and therapeutic development. It is a key component in workflows for mRNA vaccine optimization, gene editing, and protein replacement therapies. Protocols for LNP formulation with SM-102 are detailed in the C1042 kit documentation, ensuring reproducibility. For protocol optimization and troubleshooting, see SM-102 Lipid Nanoparticles: Optimizing mRNA Delivery Workflows; this article extends those protocols with benchmarked performance data and cross-validated machine learning predictions.

    Common Pitfalls or Misconceptions

    • Not all LNPs are equivalent: SM-102 is validated but may not outperform other ionizable lipids (e.g., MC3) in every assay or animal model (Wang et al., 2022).
    • Concentration sensitivity: Exceeding recommended SM-102 concentrations (>300 μM) can increase cytotoxicity, compromising transfection efficiency (APExBIO, datasheet).
    • Not suitable for non-mRNA payloads: SM-102 LNPs are optimized for mRNA and may not be appropriate for DNA or small molecule delivery without protocol adaptations.
    • Storage and formulation: Incorrect storage conditions or improper mixing can destabilize LNPs, reducing delivery efficiency (APExBIO, C1042 kit instructions).
    • Clinical translation limits: While widely used in research and preclinical workflows, regulatory approval for clinical use depends on rigorous safety and batch consistency studies.

    Workflow Integration & Parameters

    SM-102 is typically formulated in LNPs with cholesterol, DSPC, and PEG-lipid at molar ratios optimized for payload and route of administration. Standard protocols involve mixing SM-102 with helper lipids in ethanol, followed by rapid mixing with aqueous mRNA under controlled pH (see APExBIO, C1042 kit). Typical working concentrations for SM-102 range from 100–300 μM in in vitro transfection assays. LNPs should be characterized for size (typically 80–120 nm), polydispersity, and encapsulation efficiency prior to use. For real-world workflow strategies and troubleshooting, see SM-102 Lipid Nanoparticles: Advanced mRNA Delivery Workflows, which this article updates with latest experimental benchmarks and machine learning model insights. Comparative studies recommend batch testing and iterative optimization for each mRNA payload (Wang et al., 2022).

    Conclusion & Outlook

    SM-102 is a validated, versatile ionizable lipid for LNP formation, facilitating high-efficiency mRNA delivery and vaccine development. Its performance is supported by empirical studies and advanced predictive modeling. Ongoing research is refining LNP formulations, with SM-102 remaining a key benchmark. As mRNA therapeutics expand, precise formulation, batch control, and mechanistic understanding will be critical for translational success. For full specifications and ordering, see the APExBIO SM-102 product page.